Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...
Find MoreEczema is an umbrella term comprising skin disorders characterised by dry, discoloured, itchy and inflamed skin. Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder affecting the hands. In a substantial number of patients, HE can develop into a chronic...
Find MoreAtopic dermatitis, also known as atopic eczema, is a condition that results in itchy, scaly and red skin. It is an inflammatory skin disease which is a common recurrent form of skin allergy. Acute flare-ups of eczematous pruritic lesions mainly categorise atopic dermatitis over dry skin due to high levels ...
Find MoreCambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...
Find MoreActinic keratosis is also known as a solar keratosis is considered as precancerous or an early form of cutaneous squamous cell carcinoma. It is characterized by rough, erythematous patches with scaly macules or papules on the skin. It is caused by prolonged exposure to the sun and extensive expos...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.